Diabetic Retinopathy

Mental health issues, lack of awareness, transportation difficulties and other factors contributed to diabetic retinopathy screening nonattendance among patients with diabetes, according to a study published in Cureus.

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for OTX-TKI, a tyrosine kinase inhibitor designed to block VEGFR-1, VEGFR-2 and VEGFR-3.

KOLOA, Hawaii — Patients with diabetic retinopathy need special care while pregnant, according to a speaker at Retina 2025.

Throughout history, all medical decision-making has relied upon anecdote, expert opinion, and cumbersome and limited clinical trials with delayed or nonexistent post hoc analysis and validation.

CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Michael S. Ip, MD, discusses the available treatments for nonproliferative diabetic retinopathy.

Opus Genetics and the FDA have reached an agreement on a special protocol assessment for a phase 3 clinical trial investigating oral APX3330 for the treatment of moderate to severe nonproliferative diabetic retinopathy.

INDIANAPOLIS — APX3330, an investigational oral treatment for diabetic retinopathy, reduced the development of proliferative diabetic retinopathy vs. placebo among high-risk patients, according to a poster presented at Academy 2024.

Eylea HD improved vision with extended dosing intervals in patients with macular edema following retinal vein occlusion in the phase 3 QUASAR trial, according to a press release from Regeneron.

Ocular Therapeutix announced that more than 300 patients have been randomly assigned in the SOL-1 phase 3 trial for Axpaxli, an investigational axitinib intravitreal implant for wet age-related macular degeneration.

Catch up on Healio’s news in diabetic retinopathy for Diabetes Awareness Month.